Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05322005
Other study ID # DDM22M
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 26, 2020
Est. completion date December 31, 2024

Study information

Verified date June 2023
Source Mastelli S.r.l
Contact Giulia Cattarini Mastelli, Dr.ssa
Phone Tel. (+39) 0184 5111 21
Email dirmed@mastelli.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized multicentre study for the evaluation of the clinical performance and safaty of the augmentation-to-surgery and conservative treatments for the degenerative meniscopathies, with injection of polynucleotide gel.


Description:

Meniscal tear plays a significant role among the multitude of ethiologies of knee pain. In the setting of chronic meniscus degeneration, healing potential remains low due to a vascular penetration of less than one-third of the adult meniscus. Currently, both conservative and surgical modalities can be utilized in the treatment of the painful degenerative menisci, and no gold standard treatment has been identified. Polynucleotide gel Condrotide® is a polynucleotide solution, used in case of degenerative painful join pathologies, favouring the physiological mechanism of joint repair because of the capacity to normalize the viscosity of synovial fluid and supposed to improve the joint trophism. The present study aims at evaluating the capacity of the polynucleotide gel injection to stimulate healing and slow down progression of meniscal degeneration, through augmentation-to-surgery and conservative treatments for the degenerative meniscopathies.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female subjects with age between 18 and 65 years 2. Presence of symptomatic degenerative meniscus tear 3. Presence of one of the following unilateral symptoms: pain, catching, or locking of the knee 4. Non responsive to physical therapy for at least 3-4 weeks 5. Be in neutral alignment +/- 5 degrees of the mechanical axis 6. Subject must be physically and mentally willing and able to comply with the study follow-up schedule 7. Subject must sign Ethic committe approved informed consent 8. Subject is willing and able to comply with all study procedures, including visits and diagnostic procedures Exclusion Criteria: 1. Radiographic osteoarthritis of the knee in any compartment greater than Kellgren-Lawrence (KL) grade 3. 2. Presence of bone marrow edema (BME) at the index knee. 3. Presence of knee instability. 4. Have a varus or valgus knee deformity > 5 degrees. 5. Have meniscal roots tears. 6. Have discoid meniscus. 7. Have patella instability or non-anatomically positioned patella. 8. Have a knee flexion contracture > 10 degrees. 9. Be unable to flex the knee to 90 degrees. 10. Have a leg length discrepancy causing a noticeable limp. 11. Have an active infection or tumor. 12. Have any type of knee joint inflammatory disease including Sjogren's syndrome. 13. Have neuropathic knee osteoarthropathy, also known as Charcot joint. 14. Any disorder or impairment that would interfere with evaluation of outcomes measures, such as neurological, degenerative muscular, psychiatric or cognitive conditions. 15. Participation to another clinical trial or clinical investigation in the previous 3 months. 16. BMI > 35. 17. Prior knee arthroscopy within 6 months of study enrolment. 18. Unable to have an MRI scan. 19. Known allergy, sensitivity or intolerance to any of the components of the investigational device or to products originating from fish. 20. Positive history of human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C virus antibodies. 21. Autoimmune diseases, rheumatoid disease eg. Lupus erythematosus. 22. The subject is currently being treated with radiation and or chemotherapy. 23. Previous or ongoing alcohol abuse or dependence, use of illicit drugs within 1 year prior to enrolment. 24. Patients who are pregnant or planning to become pregnant during the planned period of participation in the study or who are breastfeeding. Women of child-bearing age must consent to use and actually make use of a highly effective contraceptive method, considered acceptable by the investigator, for the whole study duration. 25. Does not agree to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
partial meniscectomy
Arthroscopic procedure
Device:
Condrotide® (polynucleotides gel: class III medical device)
Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

Locations

Country Name City State
Belgium Peter Verdonk Deurne
Italy Elizaveta Kon Milan

Sponsors (2)

Lead Sponsor Collaborator
Mastelli S.r.l Latis S.r.l.

Countries where clinical trial is conducted

Belgium,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Knee Injury Osteoarthritis Outcome Score (KOOS) will be measured The change of overall KOOS score will be evaluated from baseline (V1) to 6 (V6), 12 (V7), and 24 (V8) months after treatment completion.
An improvement of 10 points in the score will be considered success.
The KOOS score assesses; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems.
24 months (end of follow up)
Secondary The change of the radiological assessment of the cartilage by a 5-points Likert scale Likert scale scoring: 0=worsened; 1= not worsened or improved; 2= slightly improved; 3= improved; 4= very much improved). The articular cartilage and meniscal appearance change will be evaluated from baseline (V1) to 6 (V6), 12 (V7), 24 (V8) months after treatment completion (T0). 24 months
Secondary The change of the International Knee Documentation Committee (IKDC Questionnaire) Is a knee-specific patient-reported outcome measure. Scores are obtained by summing the individual items, then transforming the crude total to a scaled number that ranges from 0 to 100. This final number is interpreted as a measure of function with higher scores representing higher levels of function. 24 months
Secondary The change of the Tegner activity score from baseline (V1) to 3 (V5), 6 (V6), 12 (V7), 24 (V8) months after treatment completion (T0). The Tegner activity scale is a one-item score evaluating work and sports activities on a scale of 0 to 10. Zero represents disability. 24 months
Secondary AE and device deficiencies Reporting Will be evaluated:
number and typology of device- or procedure-related serious adverse events (SAEs)
the number and typology of all other adverse events (AEs) or SAEs;
the number and typology of device deficiencies (DD)
24 months
See also
  Status Clinical Trial Phase
Completed NCT05875480 - The Effectiveness of Telerehabilitation After Arthroscopic Meniscus Repair N/A
Terminated NCT01256788 - Post-op Treatment With Hyaluronic Acid Injections N/A
Not yet recruiting NCT06045884 - FNB in Meniscal Tear Under GA N/A
Not yet recruiting NCT06048341 - FNB in Meniscal Tear Under SA N/A
Completed NCT06227078 - Effects of Kinesiotaping and Physiotherapy in Grade 2 Osteoarthritis Following Degenerative Meniscal Tears N/A
Completed NCT04956393 - The SOAR (Stop OsteoARthritis) Program Proof-of-Concept Study N/A
Recruiting NCT05882591 - Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment N/A
Completed NCT02100059 - Motor and Sensory Deficits Following Partial Meniscectomy N/A
Completed NCT05370937 - Clınıcal Results of Evelator and Free Knot Methods In Medial Menıscus Posterior Root Tears N/A
Completed NCT01931735 - Prospective Trial of Arthroscopic Meniscectomy for Degenerative Meniscus Tears N/A
Completed NCT02237001 - Study of Suture Repair of Torn Meniscus in the Knee N/A
Active, not recruiting NCT04361487 - Circumferential Compression STITCH Repairs of Complex and Horizontal Cleavage Meniscal Tears
Completed NCT06409715 - Addressing Kinesiophobia in Post-Meniscoplasty Patients Through Progressive Muscle Relaxation Training and Acupressure N/A
Enrolling by invitation NCT04641351 - Corticosteroid Meniscectomy Randomized Trial Phase 4
Recruiting NCT05909865 - PRedIcting MEniscal Tears Outcomes After Physical Therapy Treatment N/A
Enrolling by invitation NCT03037242 - Outcomes of Meniscus Root Repair Using a Transtibial Pullout Technique N/A
Recruiting NCT05799196 - The Effectiveness of the Microfracture Technique in the Meniscal Healing
Recruiting NCT05261360 - Clinical Efficacy of Exosome in Degenerative Meniscal Injury Phase 2
Completed NCT05020938 - Long Term Follow-Up of KNEE PAIN Patients Accompanying Meniscus Tear
Recruiting NCT05335252 - Dronabinol After Arthroscopic Surgery Phase 3